Wellthy Therapeutics is an up-and-coming Indian startup that develops a prescription-only digital therapeutic (DTx) that is to be used to support treatment and the management of chronic diseases like diabetes. Based in India, the world's fastest-growing diabetes market, it is in an attractive position for companies looking to penetrate the Indian diabetes market. Wellthy has fully leveraged this position. It partnered with Roche to run a clinical study to test the test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's DTx. The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The company has also since been inducted into Bayer's highly competitive digital health accelerator, G4A (Grants for Apps). Wellthy continues to build on its momentum and has now inked a collaboration with Spanish pharmaceutical Ferrer.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)